Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Withdrawn before enrolling · Not applicable · Has a placebo group

Conditions studied: Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension

In brief

The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.

Key facts

Study ID

NCT01645826

Run by

University of South Florida

People needed

0

Starts

2012-07-01

Expected to finish

2014-09-01

Last updated by the study team

2018-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants
• Confirmed WHO class I pulmonary arterial hypertension
• Nitric Oxide Non-Responders on right heart catheterization
• Experience dyspnea, NYHA III-IV with poor oxygenation and quality of life despite standard treatments
• Must be able to swallow medications

You may not qualify if…

• Pulmonary hypertension secondary to 1) elevations in pulmonary venous pressures (i.e. left heart disease), 2) chronic hypoxemic states from lung diseases such as COPD, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude and developmental abnormalities 3) chronic thromboembolic disease, 4) sarcoidosis, 5) Lymphangiomyomatosis, 5) Pulmonary Langerhans Cell Histiocytosis
• Already on a calcium channel blocker
• Systolic blood pressure less than 90
• Heart rate less than 55
• Pregnant
• Cannot sign informed consent
• Right heart failure
• Pulmonary Veno-occlusive disease

Where it is running

• University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.